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Age-related alterations of membrane lipids in brain cell membranes together with
high blood cholesterol are considered as major risk factors for Alzheimer’s disease.
Yet the molecular mechanisms by which these factors increase Alzheimer’s risk are
mostly unknown. In lipid raft domains of the plasma membrane, neurotoxic Alzheimer’s
beta-amyloid (Abeta) peptides interact with both cholesterol and ganglioside GM1. Recent
data also suggested that cholesterol could stimulate the binding of Abeta to GM1 through
conformational modulation of the ganglioside headgroup. Here we used a combination
of physicochemical and molecular modeling approaches to decipher the mechanisms of
cholesterol-assisted binding of Abeta to GM1. With the aim of decoupling the effect of
cholesterol on GM1 from direct Abeta-cholesterol interactions, we designed a minimal
peptide (Abeta5-16) containing the GM1-binding domain but lacking the amino acid
residues involved in cholesterol recognition. Using the Langmuir technique, we showed
that cholesterol (but not phosphatidylcholine or sphingomyelin) significantly accelerates
the interaction of Abeta5-16 with GM1. Molecular dynamics simulations suggested that
Abeta5-16 interacts with a cholesterol-stabilized dimer of GM1. The main structural
effect of cholesterol is to establish a hydrogen-bond between its own OH group and
the glycosidic-bond linking ceramide to the glycone part of GM1, thereby inducing a
tilt in the glycolipid headgroup. This fine conformational tuning stabilizes the active
conformation of the GM1 dimer whose headgroups, oriented in two opposite directions,
form a chalice-shaped receptacle for Abeta. These data give new mechanistic insights
into the stimulatory effect of cholesterol on Abeta/GM1 interactions. They also support
the emerging concept that cholesterol is a universal modulator of protein-glycolipid
interactions in the broader context of membrane recognition processes.
Keywords: Alzheimer, cholesterol, ganglioside, GM1, lipid raft, lipid–lipid interaction, Langmuir monolayer,
molecular modeling
INTRODUCTION
Age and high blood cholesterol are among the major non-genetic
risk factors for Alzheimer’s disease (Pappolla et al., 2003; Mayeux
and Stern, 2012). We still do not know exactly why these factors
increase Alzheimer’s risk. However, a growing body of evidence
suggests that the plasma membrane of neural cells plays a key
role in the pathophysiology of the disease (Lukiw, 2013). Analyses
of the lipid content of brain cell membranes during aging have
revealed an increase in several types of lipids, including choles-
terol and sphingolipids (Shinitzky, 1987). These lipids are con-
centrated in plasma membrane microdomains referred to as lipid
rafts (Fantini et al., 2002). By modulating the lipid content of
lipid rafts, age and high cholesterol could synergetically affect
the organization and the physico-chemical properties of these
domains, providing a favorable environment for the oligomer-
ization and/or aggregation of Alzheimer’s β-amyloid peptides (Di
Paolo and Kim, 2012).
The proteolytic cleavage of the Alzheimer’s protein precursor
APP is a cholesterol-dependent process that occurs in lipid rafts
(Ehehalt et al., 2003). Alzheimer’s β-amyloid peptides Aβ1-40 and
Aβ1-42 have a high affinity for these microdomains (Fantini and
Yahi, 2010). Indeed, β-amyloid peptides interact with GM1, a
ganglioside abundantly expressed in neural cell membranes and
concentrated in lipid rafts (Ariga et al., 2011). A large body of
data has conclusively demonstrated that GM1 plays a central role
in the generation of toxic Aβ fibrils (Choo-Smith et al., 1997;
Kakio et al., 2003; Hayashi et al., 2004; Wakabayashi et al., 2005;
Chi et al., 2007; Matsuzaki et al., 2007, 2010; Okada et al., 2007;
Yanagisawa, 2011; Matsubara et al., 2013). Interestingly, the inter-
action of Aβ with GM1 is cholesterol-dependent (Kakio et al.,
2001; Okada et al., 2008; Yahi et al., 2010). Specifically, increasing
the cholesterol content of lipid vesicles has been shown to facili-
tate the binding of Aβ to the membrane by altering the binding
capacity, but not the binding affinity (Kakio et al., 2001).
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There are two possible mechanisms by which cholesterol could
improve the binding of Aβ peptides to GM1/cholesterol mem-
branes. On one hand, Aβ could directly interact with cholesterol.
On the other hand, cholesterol could indirectly affect Aβ bind-
ing to GM1 through a modulation of ganglioside conformation.
As a matter of fact, Aβ contains a high affinity cholesterol-
binding domain (segment 22–35) allowing a functional inter-
action of the peptide with membrane cholesterol (Di Scala
et al., 2013). Moreover, direct binding of GM1 to Aβ has been
evidenced through different experimental approaches including
NMR (Williamson et al., 2006; Utsumi et al., 2009; Yagi-Utsumi
et al., 2010), fluorescence titration (Ikeda and Matsuzaki, 2008),
atomic force microscopy (Matsubara et al., 2013), and Langmuir
monolayers (Thakur et al., 2009; Fantini and Yahi, 2011). The
GM1-binding domain of Aβ has been delineated to a linear seg-
ment encompassing amino acid residues 5–16 (Fantini and Yahi,
2011). Because the binding sites for GM1 and cholesterol do not
overlap, it can be assumed that Aβ1-40 and Aβ1-42 can bind to
both lipids in a lipid raft domain. This particular situation ren-
ders difficult the experimental study of the second theoretical
mechanism of cholesterol-stimulated Aβ binding to GM1, i.e., a
conformational effect of cholesterol on GM1.
In the present study, we circumvent this difficulty by analyzing
the effect of cholesterol on the interaction between GM1 andAβ5-
16, a functional GM1-binding peptide (Fantini and Yahi, 2011)
that does not contain the cholesterol-binding domain of Aβ. We
showed that cholesterol accelerates the interaction between Aβ5-
16 and GM1 through a hydrogen-bond-driven conformational
effect involving the glycone part of GM1. These data shed some
light on the molecular mechanisms by which cholesterol and
GM1 cooperate to boost the association of Aβ with lipid raft
domains. From a broader perspective, this study is in line with the
emerging concept that cholesterol functions as an intramembrane
switch that controls ligand binding to GSL receptors (Fantini and
Yahi, 2010; Yahi et al., 2010; Coskun and Simons, 2011; Lingwood,
2011; Lingwood et al., 2011).
MATERIALS AND METHODS
MATERIALS
Kerasin (galactosylceramide, GalCer), GM1, and GM3 were
obtained from Matreya (Pleasant Gap, PA). Lactosylceramide
(LacCer) was purchased from Avanti Polar Lipids (Alabaster,
AL). Cholesterol, sphingomyelin (SM), palmitoyl-oleoyl-
phosphatidylcholine (POPC), and the Aβ1-40 peptide were
from Sigma (Saint-Quentin Fallavier, France). The Aβ5-16
peptide was from Schafer (Denmark). All lipids were dissolved
at a concentration of 1mg.mL−1 in hexane:chloroform:ethanol
(11:5:4, vol:vol:vol). Ultrapure water (pH 7.0, surface tension
72.8mN.m−1, resistivity >18.2M .cm) was obtained from
Biorad (Marnes-La-Coquette, France).
LIPID MONOLAYER ASSAY
Peptide-lipid interactions were studied at 25◦C with the
Langmuir film balance technique (Thakur et al., 2009). The
interaction of a peptide with a reconstituted membrane is an
interfacial phenomenon which can be studied by surface pressure
(π) measurements of lipid monolayers at the air–water interface.
The underlying idea is that the insertion of the peptide in the lipid
monolayer can be detected, at constant area, by an increase in the
surface pressure. This increase in the surface pressure is caused
by the insertion of the peptide between the polar heads of vic-
inal glycolipids in the monolayer, which is not counterbalanced
by an increase of the area of the monolayer. This effect can be
followed kinetically by real-time surface pressure measurements
after injecting the peptide into the aqueous subphase underneath
the lipid monolayer as described previously (Fantini et al., 2006;
Yahi et al., 2010). Monomolecular films of the indicated lipid were
spread on ultrapure water subphases totally devoid of any surfac-
tant contaminant. To allow comparative studies, all monolayers
were prepared at an initial surface pressure of 17–20mN.m−1,
which corresponds to a fully compressible film. After spreading of
the film, 5min was allowed for solvent evaporation. The Aβ5-16
peptide (fresh monomeric solution used at a final concentration
of 10−5 M in ultrapure water) was then injected in the subphase
(pH 7) with a 10-μl Hamilton syringe, and pressure increases
produced were continuously recorded as a function of time. The
data were analyzed with the FilmWareX program (Kibron Inc.).
The accuracy of the system under our experimental conditions
was ±0.25mN.m−1 for surface pressure. The initial velocity (vi)
of the insertion process is expressed as mN.m−1.min−1. The dif-
ference between the maximal (πmax) and the initial (πi) surface
pressure values allows to calculate the maximal surface pressure
increase (πmax) induced by the peptide (expressed inmN.m−1).
Mixed monolayers (Hammache et al., 2000) were prepared from
stock solutions of lipid mixtures immediately before use.
IN SILICO STUDIES
The starting structure of Aβ1-40 (Di Scala et al., 2013) and
of Aβ5-16 (Fantini and Yahi, 2011) were derived from a NMR
structure of Aβ1-40 in solution in a water–micelle environment
(Coles et al., 1998), using the PDB entry 1BA4. Geometry opti-
mization was first achieved using the unconstrained optimiza-
tion rendered by the Polak–Ribière conjugate gradient algorithm.
Molecular dynamics simulations were then performed for vari-
ous periods of times ranging from 10 ps to 10 ns in vacuo with
the Bio+ (CHARMM) force field (Singh et al., 2009) of the
Hyperchem software suite (ChemCad, Obernay, France). The
energy of interaction was determined with theMolegroMolecular
Viewer (Thomsen and Christensen, 2006). Galactose-cholesterol
and GM1-cholesterol models were obtained with the Hyperchem
program as described previously (Yahi et al., 2010), by anal-
ogy with the GSL structures published by Pasher and Sundell
(1977). Lipid-protein complexes were visualized with the PyMOL
Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC.
RESULTS
CHOLESTEROL STIMULATES THE INTERACTION OF Aβ1-40 WITH GSLs
When injected underneath amonolayer of pure ganglioside GM1,
the Aβ1-40 peptide induced a gradual increase of the surface pres-
sure (Figure 1A). When the experiment was performed with a
mixed cholesterol/GM1 monolayer (1/1, mol/mol), the interac-
tion with Aβ1-40 was significantly accelerated, and the maximal
surface pressure increase (πmax) induced by the peptide reached
a highest value (10mN.m−1 with cholesterol, compared with
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FIGURE 1 | Effects of cholesterol on GSL-Aβ1-40 interactions. (A)
Kinetics of Aβ1-40 insertion into a monolayer of GM1 in either the absence
(red bars) or presence of cholesterol (black bars). The data show the
evolution of the surface pressure following the injection of Aβ1-40 (1μM)
in the aqueous subphase underneath the monolayer. Each experiment was
performed in triplicate and one representative curve is shown (S.D. <10%).
(B) Maximal surface pressure increase (πmax) induced by Aβ1-40 on
various GSL monolayers. The GSLs differed in the number of sugar units
in their glycone part: 1 (GalCer), 2 (LacCer), 3 (GM3), and 5 (GM1).
(C) Mean increase of the initial velocity (vi) induced by Aβ1-40 on these
GSL monolayers. Data are expressed as the mean ± S.D. of three
independent experiments.
6mN.m−1 with GM1 alone after 1 h of incubation). As previously
reported (Yahi et al., 2010), this stimulatory effect of choles-
terol was observed with some GSLs other than GM1, i.e., GalCer,
LacCer, and GM3. Yet it is interesting to note that the intensity
of the cholesterol effect was clearly dependent on the number of
sugar units that constitute the glycone part of the GSLs. Indeed,
both the amplitude (πmax) and the vi of the phenomenon
decreased as the number of sugars increased (Figures 1B,C). As
a matter of fact, all these mixed cholesterol/GSL monolayers con-
tain the same molar amount of cholesterol. Accordingly, one can
assume that Aβ1-40 does not directly interact with cholesterol,
and that the peptide binds to the glycone part of the GSLs through
a cholesterol-dependent mechanism (Yahi et al., 2010). In the
present study, we have designed a new Aβ-derived peptide probe
to investigate further the mechanistic basis of GM1, cholesterol
and Aβ interactions in a raft-mimicking environment.
Aβ5-16 CONTAINS THE GM1-BINDING DOMAIN OF Aβ1-40 BUT DOES
NOT INTERACTWITH CHOLESTEROL
Our recent molecular modeling studies coupled with physico-
chemical measurements of Aβ-lipid interactions suggested that
the N-ter part of Aβ contains a glycolipid-binding domain
(fragment 5–16) and the C-ter part a cholesterol-binding site
(fragment 22–35). Yet we did not know whether the topol-
ogy of Aβ in a membrane environment is consistent with
dual recognition of GM1 and cholesterol. To assess whether
the same Aβ1-40 peptide could interact with both GM1 and
cholesterol, we performed a new series of molecular dynamics
simulations. We used the individual structures of GM1-bound
Aβ5-16 (Fantini and Yahi, 2011) and cholesterol-bound Aβ22-35
(Di Scala et al., 2013), and reintroduced them in the struc-
ture of a micellar, membrane-consistent topology of Aβ1-40
(Coles et al., 1998). The orientation of cholesterol in this tri-
molecular complex determined the mode of insertion of the Aβ
peptide in the membrane. Specifically, cholesterol was embed-
ded in the membrane and the sugar part of GM1 was pro-
truding toward the extracellular milieu. With this geometry, the
GM1-binding domain (Aβ5-16) was totally excluded from the
membrane whereas the cholesterol-binding site (Aβ22-35) was
totally immersed in the membrane (Figure 2, left panel). There
was no physical contact between cholesterol and the 5–16 frag-
ment of Aβ. Correspondingly, a model of the Aβ5-16 peptide
bound to a GM1/cholesterol membrane (Figure 2, right panel)
could be generated, with the following properties: (1) Aβ5-16
www.frontiersin.org June 2013 | Volume 4 | Article 120 | 3
Fantini et al. How cholesterol promotes Abeta-GM1 interaction
FIGURE 2 | Topology of lipid-binding domains in Aβ1-40 and Aβ5-16.On
the left panel, Aβ1-40 interacts with both GM1 (domain 5–16) and cholesterol
(domain 22–35). In this complex, Aβ1-40 is in orange grid rendering, GM1 is
rust-colored, and cholesterol is in green. Note the side chain of Lys-28 which
wraps around the cholesterol molecule colored in green. Another cholesterol
molecule (in yellow) interacts with the membrane-embeddedpart of GM1. The
polar-apolar limit of the membrane is marked by a white dotted line. On the
right panel, Aβ5-16 interacts with two GM1molecules (rust and blue). Each of
these GM1molecules interacts with cholesterol. Note that these cholesterol
molecules are embedded in the membrane (under the dotted line) and do not
physically interact with Aβ5-16. Thesemolecular models were obtained by
molecular dynamics simulations as explained in Materials andMethods.
interacts with GM1, but not with cholesterol; (2) cholesterol
interacts with GM1 in such a way that it can influence the con-
formation of the sugar headgroup. For these reasons, studying
the interaction of Aβ5-16 with a GM1/cholesterol membrane
has the unique advantage of decoupling the direct binding of
Aβ to GM1 from indirect cholesterol-mediated effects on GM1
conformation.
CHOLESTEROL STIMULATES THE INTERACTION OF Aβ5-16 WITH GM1
A monolayer of pure ganglioside GM1 was prepared and
probed with the Aβ5-16 peptide added in the aqueous subphase
(Figure 3). Following a lag time of 5min, the surface pressure
started to gradually increase, reaching 8mN.m−1 after 50min of
incubation.
When Aβ5-16 was injected underneath a mixed choles-
terol/GM1 monolayer, the surface pressure increased immedi-
ately. After 50min of incubation, the surface pressure increase
was 14mN.m−1. A detailed analysis of the first 5min of incu-
bation with the peptide confirmed the absence of lag phase in
mixed cholesterol/GM1 monolayers (Figure 4A). In this case, the
vi of the interaction was estimated to 0.73mN.m−1.min−1. For
pure GM1monolayers, (vi) was 0.06mN.m−1.min−1. This corre-
sponded to a strong cholesterol-evoked stimulation of vi (× 12
times). For the sake of comparison, we studied the interaction
of Aβ5-16 with a monolayer of pure cholesterol (Figure 4B).
When the peptide was injected underneath this cholesterol mono-
layer, the surface pressure did not increase but first decreased and
then gradually returned to null values. This indicated that the
cholesterol-induced stimulation of Aβ5-16 binding to GM1 was
FIGURE 3 | Effect of cholesterol on the GM1-Aβ5-16 interaction. The
data show the evolution of the surface pressure following the injection of
Aβ5-16 (10μM) in the aqueous subphase underneath a GM1 monolayer in
either the absence (full squares) or presence of cholesterol (open squares).
Each experiment was performed in triplicate and one representative curve
is shown (S.D. <10%).
not due to a direct interaction of the peptide with cholesterol, in
full agreement with our modeling studies (Figure 2).
THE EFFECT OF CHOLESTEROL IS SPECIFIC
A possible interpretation of our data is that the presence of
cholesterol within the GM1 monolayer could dilute the sugar
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FIGURE 4 | Cholesterol accelerates the interaction of Aβ5-16 with
GM1. (A) Initial phase of interaction of Aβ-16 with pure GM1 (full
squares) or mixed GM1-cholesterol monolayers (open squares). (B)
Interaction of Aβ-16 with a cholesterol monolayer. Each experiment was
performed in triplicate and one representative curve is shown
(S.D. <10%).
headgroups of the ganglioside, resulting in an increase of acces-
sibility of Aβ5-16 to GM1. To rule out this possibility, we pre-
pared a series of GM1 monolayers mixed with various lipids
(Figure 5). When the Aβ5-16 peptide was injected underneath
a GM1/sphingomyelin monolayer (1:1, mol:mol), the surface
pressure first decreased and then remained below the base-
line during more than 40min. Thus, not every membrane
lipid could exert the stimulatory effect of cholesterol on the
GM1/Aβ5-16 interaction, sphingomyelin (SM) being a significant
counterexample. When GM1 was mixed with palmytoyl-oleoyl-
phosphatidylcholine (POPC), there was a lag phase of 10min
before the peptide could induce any increase in the surface
pressure (Figure 5). This indicated that dilution of GM1 in a
phosphatidylcholinematrix was not sufficient to increase the vi of
the GM1/Aβ5-16 interaction (compare the kinetics of interaction
of pure GM1 with mixed GM1/phosphatidylcholine monolayers
in Figures 4, 5). Thus, phosphatidylcholine is another counterex-
ample showing that the effect of cholesterol on the GM1/Aβ5-16
interaction is highly specific. Interestingly, when a molar frac-
tion of phosphatidylcholine was replaced with cholesterol in a
mixed GM1/POPC/cholesterol (2:1:1, mol:mol:mol) monolayer,
the lag phase was no longer observed and the surface pressure
increased immediately (although more slowly than with dual
GM1/cholesterol monolayers) after the injection of the peptide
(Figure 5, inset).
CHOLESTEROL CONSTRAINS GSL CONFORMATION THROUGH A
UNIQUE MOLECULAR MECHANISM
As recently reported by our group (Yahi et al., 2010), choles-
terol induces a typical “shovel-like” conformation of kerasin (i.e.,
GalCer with a non-hydroxylated fatty acyl chain), whose unique
FIGURE 5 | The effect of cholesterol is specific.Mixed GM1/SM
(1:1, mol:mol), GM1/POPC (1:1, mol:mol), or GM1/POPC/cholesterol (2:1:1,
mol:mol:mol) were prepared and probed with Aβ5-16 (10μM) injected in
the aqueous subphase. The data show the evolution of the surface
pressure as a function of time following peptide injection underneath
GM1/POPC (full squares), GM1/POPC/cholesterol (open squares), or
GM1/SM (open triangles) monolayers. Each experiment was performed in
triplicate and one representative curve is shown (S.D. <10%).
galactosyl unit forms an angle of ca. 90◦ with the ceramide back-
bone (Figure 5). This conformation is stabilized by a hydrogen
bond involving the OH group of cholesterol (donor H-bond
group) and the oxygen atom of the glycosidic bond (acceptor
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H-bond group). In order to assess whether a similar hydrogen
bond-driven mechanism could also account for a cholesterol-
dependent effect on GM1 conformation, we performed a new
series of molecular modeling simulations of cholesterol/GM1
interactions. As shown in Figure 6, the smooth α face of choles-
terol spread along the ceramide backbone of GM1, leaving
the OH group of cholesterol in front of the oxygen atom of
the glycosidic bond. Thus, a hydrogen bond quite similar to the
one of the GalCer/cholesterol complex could also stabilize the
GM1/cholesterol complex. Correspondingly, this hydrogen bond
kept the first sugar of GM1 (a glucosyl unit) parallel and flush to
the membrane, inducing a tilt in the ganglioside structure.
CHOLESTEROLMARGINALLY AFFECTS THE BINDING AFFINITY OF
Aβ5-16 FOR GM1
Our modeling studies strongly suggested that the OH group
of cholesterol restricts the conformation of the glycone part
of various GSLs so that these GSLs adopt a typical L-shape
structure (Figure 6). This tilted structure immediately suggests
a specific orientation of the sugar headgroups in GM1 clusters.
Nevertheless, we used different starting conditions to construct a
dimer of the cholesterol/GM1 complex and we tested the ther-
modynamic stability of each complex by molecular dynamics
simulations. The structure of the most stable dimer obtained by
this way is shown in Figure 7. Both GM1 molecules interacted
through their ceramide parts in the apolar phase of the mem-
brane. Their respective sugar parts were rejected in two opposite
directions, leaving a wide empty space that is fully compatible
FIGURE 6 | Molecular dynamics simulations of cholesterol-GSL
interactions. In the cholesterol-GalCer complex (left panel), the OH of
cholesterol is a donor group that forms a hydrogen bond with the oxygen
atom of the glycosidic linkage between galactose and ceramide. A similar
[O–H. . .O] hydrogen bond is formed between cholesterol and GM1 (right
panel). In both cases, cholesterol constrains the GSL to adopt a typical
shovel-like conformation. The other contacts between cholesterol and the
GSL give rise to stabilizing van der Waals interactions between the apolar
ceramide part of the GSL and the “smooth” α face of cholesterol. The
“spiked” β face of cholesterol generally interacts with vicinal proteins in the
membrane.
with the insertion of the whole Aβ5-16 peptide (Figure 7A).
The typical shovel, L-like structure of GM1 is particularly well
visible in the side view of the complex (Figure 7B). To get a
better idea of the model, we have also shown a series of itera-
tive views accounting for a whole 360◦ rotation of the complex
(Figure 8). A detailed energetic analysis of the GM1/Aβ5-16 com-
plex (without cholesterol) revealed that one GM1 molecule inter-
acted chiefly with His-6, Glu-11, His-13, and Lys-16, whereas the
other one interacted essentially with Arg-5, His-14, and Gln-15
(Table 1). Interestingly, the presence of cholesterol did not dra-
matically increase the energy of GM1/Aβ5-16 interaction. The
main effect of GM1 was to improve the fit between GM1 and His-
6 (from −6.8 to −22.5 kJ.mol−1). Otherwise, minor increases in
the energy of interaction concerned Glu-11, Gln-15, and Lys-16.
The total energy of interaction between Aβ5-16 and the GM1
dimer was estimated to −88.4 kJ.mol−1
112.1 kJ.mol−1with cholesterol (i.e., an increase of only × 1.3).
DISCUSSION
It is now widely admitted that cholesterol is a key regulator of
membrane receptor function (Gimpl et al., 1997; Coskun and
Simons, 2011; Lingwood, 2011). Cholesterol physically inter-
acts with a broad range of membrane proteins (Fantini and
Barrantes, 2009, 2013) through several types of cholesterol-
binding domains including the consensus CRAC (Epand et al.,
2010; Jafurulla et al., 2011; Picazo-Juárez et al., 2011) and
CARC motifs (Baier et al., 2011), tilted peptides (Fantini et al.,
2011), and three-dimensional sites (Hanson et al., 2008; Paila
et al., 2009). Cholesterol also interacts with various sphingolipids
such as sphingomyelin (Mattjus and Slotte, 1996), neutral GSLs
(Slotte et al., 1993; Mahfoud et al., 2002), and gangliosides
(Radhakrishnan et al., 2000; Taïeb et al., 2009). According to
a new emerging concept, cholesterol has the unique capabil-
ity to modulate GSL accessibility through direct conformational
tuning of GSLs (Fantini and Yahi, 2010; Yahi et al., 2010;
Coskun and Simons, 2011; Lingwood, 2011; Lingwood et al.,
2011). By inducing a tilt in the GSL headgroup, cholesterol
can either prevent or improve the accessibility of GSL recep-
tors to extracellular ligands. Therefore, such GSLs may exist in
two distinct states, their sugar headgroup being either paral-
lel to the membrane (high cholesterol content) or protruding
toward the extracellular space (low cholesterol content). This
allows cholesterol to exert a binary control on GSL conforma-
tion and function. In this respect, this binary switch presents
some analogy with the phosphorylation/dephosphorylation cycle
of proteins, although in the case of cholesterol the regulation
is non-covalent. A particularly convincing argument in favor
of this concept comes from the study of sperm capacitation, a
process associated with a loss of cholesterol (Cross, 1998). As
elegantly shown by Lingwood et al. (2011), the reduction inmem-
brane cholesterol levels in sperm cells evoked the unmasking of
cryptic GSL receptor. Similarly, verotoxin binding to globotriao-
sylceramide (Gb3) in erythrocyte membrane was detected only
after methyl-β-cyclodextrin removal of cholesterol from erythro-
cytes plasma membranes (Lingwood et al., 2011). The sudden
exposure of the sugar headgroup of the GSL—that was previ-
ously maintained in a parallel orientation with respect to the
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FIGURE 7 | Molecular modeling simulations of cholesterol-GM1-Aβ5-16
interactions. Two distinct orientations of the models are shown: front view
(A) and side view (B). The shovel-like conformation of GM1 induced by
cholesterol allows a specific topology of a couple of GM1 molecules
interacting through their ceramide parts in the apolar phase of the
membrane. Namely, the sugar parts of both GM1 molecules are oriented in
two opposite directions, thereby delineating a chalice-shaped receptacle
allowing an optimal interaction with Aβ5-16. The complex is stabilized by the
H-bond between GM1 and cholesterol, and by a series of sugar-aromatic
interactions between the glycone part of GM1 and specific amino acid side
chains in Aβ5-16 (Table 1). These molecular models were obtained by
molecular dynamics simulations as explained in Materials and Methods.
membrane—explains why cholesterol depletion improves ligand
binding.
In the case of Alzheimer’s disease, the situation is com-
pletely different from that. The increase in cholesterol stimulates
Aβ binding to GM1 and subsequently promotes β-amyloid fib-
rillation (Kakio et al., 2001), and this is consistent with the
epidemiological link between high cholesterol and Alzheimer’s
disease. In a broader context, these data support the idea that
cholesterol can exert opposite effects on GSL accessibility and/or
function: (1) in some cases, ligand binding to a GSL recep-
tor can be chronically inhibited by membrane cholesterol, and
only a significant depletion of the sterol renders the GSL acces-
sible to exogenous ligands (Lingwood et al., 2011); (2) in other
cases, cholesterol improves GSL recognition by external ligands
so that any increase in membrane cholesterol content improves
the binding capacity of GSL-containing membranes (Kakio et al.,
2001). Yet, these contrasting effects of cholesterol are due to
a common molecular mechanism, i.e., the induction of a tilt
in the GSL headgroup (Yahi et al., 2010; Lingwood et al.,
2011).
A major outcome of the present study is that we could demon-
strate the indirect effect of cholesterol on the GM1/Aβ interaction
by using a truncated Aβ peptide (Aβ5-16) that recognizes GM1
but not cholesterol. Our physico-chemical data showed that the
binding of Aβ5-16 to GM1 monolayer is dramatically accel-
erated (× 12) in presence of cholesterol (Figures 3, 4). This
effect is highly specific since it was not observed when GM1
was mixed with either sphingomyelin or phosphatidylcholine
(Figure 5). Thus we could totally rule out a non-specific “dilu-
tion” effect triggered by any lipid surrounding GM1 in the
membrane. Accordingly, the effect of cholesterol could not be
trivially interpreted as the result of lipid-mediated spacing of
the sugar headgroups of ganglioside molecules. Indeed, replacing
a molar fraction of phosphatidylcholine with cholesterol in a
mixed GM1/phosphatidylcholine monolayer increased the vi of
the GM1/Aβ5-16 reaction (Figure 5). This further demonstrated
that it is actually cholesterol, and not the presence of other
“diluting” lipid molecules, that activates the binding of Aβ5-16
to GM1. In agreement with this notion, molecular dynamics
simulations suggested that cholesterol helped GM1 to acquire a
confirmation that favored the functional dimerization of GM1
gangliosides (Figure 7). With their respective sugar headgroups
rejected in two opposite direction, the GM1 dimer formed a
kind of chalice-shaped receptacle for Aβ5-16. Correspondingly,
the interaction of Aβ5-16 with a mixed cholesterol/GM1 mono-
layer occurred with no lag phase (Figure 4A). It is likely that
in absence of cholesterol, this typical conformation of GM1
molecules cannot occur spontaneously, but only after the mutual
adaptation of GM1 and Aβ5-16 structures through an induced-
fit mechanism. The latency observed before we could detect
any interaction between Aβ5-16 and GM1 (Figure 4A) strongly
supports this view. Moreover, estimations of the energy of inter-
action in GM1/Aβ5-16 in absence or presence of cholesterol
(Table 1) suggest that cholesterol does not significantly increase
the affinity of Aβ5-16 for GM1, in line with the notion that
the effect of cholesterol is chiefly a kinetic one. This is sup-
ported by both physico-chemical and in silico data. By studying
the interaction of various mutant peptides with GM1 monolay-
ers, we identified the following amino acid residues of Aβ5-16
as critical for binding to GM1: Arg-5, His-13, His-14, and Lys-
16, which act as primary binding sites for GM1 gangliosides
(Fantini and Yahi, 2011). Cholesterol marginally affected the
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FIGURE 8 | Decomposed 360◦ rotation views of the cholesterol-GM1-Aβ5-16 complex. Sixteen views resulting from regular 22.5◦ increments of the
complex are shown.
energy of interaction of these residues (Table 1). Instead, choles-
terol reinforced the interaction with auxiliary residues such as
His-6 and Gln-15, which act as accessory binding sites. Again,
these data strongly suggest that cholesterol accelerates the inter-
action of Aβ with GM1 but does not dramatically increase the
affinity of the peptide for its ganglioside receptors. By induc-
ing a specific conformation of GM1, cholesterol facilitates the
recruitment of these gangliosides into a functional dimeric unit
able to bind the Aβ peptide without further conformational
adjustment.
This conformational effect of cholesterol on GSLs is mostly
due to the establishment of a hydrogen bond between the OH
group of cholesterol (donor group) and the oxygen atom of
the glycosidic bond linking the glycone part of the GSL to
ceramide (acceptor group). Alternatively, the acceptor group for
this hydrogen bond could be the OH in C2 of the first sugar
(this OH group is oriented toward the plasma membrane and
is located at hydrogen-bond-compatible distance from the OH
of cholesterol). Such intermolecular hydrogen bonding inter-
actions between two different lipids with suitable donor and
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Table 1 | Energetics of interaction of Aβ5-16 with GM1: effect of
cholesterol.
Amino acid
residue in
Aβ5-16
1st GM1
without
cholesterol
1st GM1
with
cholesterol
2nd GM1
without
cholesterol
2nd GM1
with
cholesterol
Arg-5 − − −18.268 −19.292
His-6 −6.798 −22.475 − −
Asp-7 − − − −
Ser-8 − − − −
Gly-9 − − − −
Tyr-10 − − − −
Glu-11 −13.545 −16.374 − −
Val-12 −3.962 −3.179 − −
His-13 −10.627 −9.988 − −
His-14 − − −14.575 −15.585
Gln-15 − − −6.044 −8.721
Lys-16 −12.609 −13.499 −1.991 −3.024
Total −47.541 −65.515 −40.878 −46.622
The energy of interaction is determined after molecular docking of Aβ5-16
on GM1 in either the absence or presence of cholesterol (see Materials
and Methods). In the model shown in Figure 7, the 1st GM1 molecule is
colored in rust and the 2nd GM1 in blue.
acceptor groups (e.g., cholesterol and sphingolipids) have been
previously characterized (Boggs, 1987; Nyholm et al., 1990).
However, the involvement of the glycosidic bond (or alter-
natively the C2–OH of the first sugar) in these lipid–lipid
hydrogen-bond-driven interactions is highly significant. Because
it concerns the first glycosidic bond of the headgroup, the effect of
cholesterol is particularly important for monohexosylceramides
such as kerasin (Figure 1). Then the effect of cholesterol gradu-
ally decreases as the number of sugars increases. Nevertheless, it
remains significant enough for GM1 (which contains five sugar
units in the headgroup), so that it can be readily measured by the
reasonably sensitive Langmuir monolayer assay (Figures 3, 4).
In conclusion, our data give new mechanistic insights into
the stimulatory effect of cholesterol on Abeta/GM1 interac-
tions. By increasing the local concentration of Aβ in lipid raft
microdomains, cholesterol could either stimulate amyloid fib-
rillation (Yip et al., 2001; Matsuzaki et al., 2010) or facilitate
amyloid channel formation (Micelli et al., 2004). In any case,
this cholesterol/GM1-dependent polymerization of Aβ will elicit
acute neurotoxic effects. On the opposite, lipid raft disruption
has been shown to protect neurons against amyloid oligomer
toxicity (Malchiodi-Albedi et al., 2010). Incidentally, our data
also support the emerging concept that cholesterol is a universal
modulator of protein-glycolipid interactions in the broader con-
text of membrane recognition processes. This concept opens up
new therapeutic strategies based on the design of synthetic GSL
analogs in which the conformational effect of cholesterol is mim-
icked by a rigid chemical group such as adamantine (Mylvaganam
and Lingwood, 1999; Mahfoud et al., 2002; Lund et al., 2006).
It would be of high interest to consider such GSL/cholesterol-
based therapies (Fantini, 2007) as an alternative approach for the
treatment of Alzheimer’s and other neurodegenerative diseases.
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